The purpose of the study was to research and analyze the peculiarities of changes of some hemostasis system indices and define their possible role in the formation of a vascular lesion in the patients with compensated chronic cor pulmolale of broncho-pulmonary genesis in conditions of its comorbidity with stable coronary heart disease. Materials and methods. The retrospective study and analysis of hemostasis system indices (platelet count, thrombin time, prothrombin time, antithrombin – III, plasma tolerance to heparin, plasmin lysis, fibrinogen, soluble fibrin) in 64 patients with chronic obstructive pulmonary disease and compensated chronic cor pulmonale (29 female, 35 male, mean age – 54.6 ± 2.3) were carried out. 32 patients with the isolated pathology formed the comparative group whereas 32 patients with the comorbid coronary heart disease (exertional angina, functional class II-III, postinfarction or aterosclerotic cardiosclerosis) built the main group. The obtained research results of the patients of the main and comparative groups were compared both in groups and with the indices of practically healthy individuals (n = 15) of the same gender and age. Results and discussion. The obtained results indicated the presence of a significant increase of coagulation potential (the changes of indices of platelets, fibrinogen, plasma tolerance to heparin, antithrombin – III, and soluble fibrin) and activation of fibrinolysis system (thrombin time) and, simultaneous, its more pronounced depression (plasmin lysis) and increase of prothrombin time in case of presence of comorbid coronary heart disease in the patients with chronic cor pulmonale in conditions of chronic inflammatory process. Comorbidity promoted to the formation of disbalance of systemic correlation hemocoagulation and fibrinolysis. Our results confirm to a certain extent the following ideas of scientists: there are hypercoagulation and “exhaustion of the anticoagulant system potential” in case of combination of coronary heart disease and chronic obstructive pulmonary disease; hypercoagulation together with the oxidative stress and chronic systemic inflammation are general pathogenic mechanisms of chronic obstructive pulmonary disease and cardiovascular diseases, particularly of the coronary heart disease. Conclusion. The analysis of the changes of the hemostasis system indices in patients with compensated chronic cor pulmonale of broncho-pulmonary genesis indicates the presence of an increase of coagulation potential; the most significant changes with suppression of fibrinolytic activity are typical of the patients with comorbid coronary heart disease. The peculiarities of the hemostasis system changes in the patients with compensated chronic cor pulmonale of broncho-pulmonary genesis should be considered as a marker of the increased risk of the thrombogenic vascular complications. It should be taken into account for treatment-diagnostic strategy formation

Keywords: chronic cor pulmonale, coronary heart disease, comorbidity, hemostasis system

Full text: PDF (Ukr) 265K

1. Feshchenko YuI, Ostrovsʹkyy MM, Makoyda IYa. Modyfikatsiya perebihu khronichnoho obstruktyvnoho zakhvoryuvannya lehenʹ: mif chy nahalʹni realiyi sjohodennya? [Modification of clinical course of chronic obstructive pulmonary disease: a myth or essential reality of present?]. Ukr Pulmon Zh. 2022;30(1):47-51. [Ukrainian]. https://doi.org/10.31215/2306-4927-2022-30-1-47-51
2. Ilashchuk TO, Mykytyuk OP, Chobanu YaV. Osoblyvosti poyednanoho perebihu khronichnoho obstruktyvnoho zakhvoryuvannya lehenʹ ta khronichnoyi ishemichnoyi khvoroby sertsya (ohlyad literatury) [The peculiarities of the combined course of chronic obstructive pulmonary disease and coronary heart disease (Literature review)]. Klin Eksp Patoloh. 2021;2(76):96-104. https://doi.org/10.24061/1727-4338.XX.2.76.2021.14
3. Global initiative for chronic obstructive lung disease (GOLD) Global Strategy for Diagnosis, Management and Prevention of COPD. 2020 Available from: https://goldcopd.org/wp-content/ uploads/2019/11/GOLD-2020-REPORT ver1.0wms.pdf
4. Morgan AD, Zakeri R, Quint JK. Defining the relationship between COPD and CVD: what are the implicationsfor clinical practice? Ther Adv Respir Dis. 2018;12:1-16. PMID: 29355081. PMCID: PMC5937157. https://doi.org/10.1177/1753465817750524
5. Trinkmann F, Saur J, Borggrefe M, Akin I Cardiovascular Comorbidities in Chronic Obstructive Pulmonary Disease (COPD)—Current Considerations for Clinical Practice. J Clin Med. 2019 Jan 10;8(1):69. PMID: 30634565. PMCID: PMC6352261. doi:10.3390/jcm8010069
6. Caughey GE, Ramsay EN, Vitry AI, Gilbert AL, Luszcz MA, Ryan P, et al. Comorbid chronic diseases, discordant impact on mortality in older people: a 14-year longitudinal population study. J Epidemiol Community Health. 2010 Dec; 64(12):1036-42. PMID: 19854745. https://doi.org/10.1136/jech.2009.088260
7. Bolotnova TV, Okonechnikova NS, Andreyeva OV. Clinical peculiarities of ischemic heart disease and arterial hypertension in conditions of comorbidity with chronic obstructive pulmonary disease in elderly patients. Med Nauka Obraz Ur. 2016; 17 (4): 5–9.
8. Ostroumova OD, Kochetkov AI. Chronic obstructive pulmonary disease and comorbid cardiovascular disease: in the context of guidelines. Consilium Medicum. 2018;20(1):54–61. https://doi.org/10.26442/2075-1753_2018.1.54-61
9. Voynarovsʹka HP, Asanov EO. Ishemichna khvoroba sertsya ta khronichne obstruktyvne zakhvoryuvannya lehenʹ: aktualʹna problema komorbidnosti u vnutrishniy medytsyni [Ischemic heart disease and chronic obstructive pulmonary disease: actual problem of comorbidity in internal medicine] ScienceRise: Medical Science. 2020 Trav 31;3(36): 20-4. [Ukrainian]. https://doi.org/10.15587/2519-4798.2020.203968
10. Petrov YeYe, Burmak YuG, Treumova SI, Ivanytsʹka TA. Porivnyalʹna kharakterystyka deyakykh pokaznykiv systemy hemostazu u khvorykh na kompensovane khronichne leheneve sertse bronkho-lehenevoho genezu ta v umovakh yoho komor bidnosti z hipertonichnoyu khvoroboyu [Comparative characteristics of some hemostasis system indices in the patients with compensated chronic cor pulmonale of broncho-pulmonary genesis and in conditions of its comorbidity with hypertensive disease]. Visnyk problem biolohiyi i medytsyny. 2021;1(159):109-12. [Ukrainian]. https://doi.org/10.29254/2077-4214-2021-1-159-109-112
11. Fedotova LA. Functional activity of hemostasis and fibrinolysis in patients with ischemic heart disease in the course of cardiocyte protective therapy. Krovoobih ta hemostaz. 2014;1/2:110-14.
12. Pastushyna AI. Aktyvnistʹ protsesiv hemokoahulyatsiyi pry komorbidnomu perebihu hipertonichnoyi khvoroby ta ishemichnoyi khvoroby sertsya [Activity of coagulation processes with comorbid hypertension and coronary heart disease]. Liky Ukrayiny. 2021 Lyp 16;5(251):35–8. [Ukrainian]. https://doi.org/10.37987/1997-9894.2021.5(251).238140
13. Wu W, Liu R, Chen L, Chen H, Zhang S. Disequilibrium of Blood Coagulation and Fibrinolytic System in Patients With Coronary Artery Ectasia. Medicine (Baltimore). 2016 Feb;95(8):2779. PMID: 26937905. PMCID: PMC4779002. https://doi.org/10.1097/MD.0000000000002779
14. Fedotova LA, Zorin VN, Plastun MYu. Haemostasis and fibrinolysis in ischemic heart disease and hypertension. Tavricheskiy mediko-biologicheskiy vestnik. 2013; 4 (64):183-86.
15. Sokolov YeI, Grishina TI, Shtin SR. The effect of von Willebrandt factor and endotelin-1 on the formation of thrombotic status in ischemic heart disease. Kardiologiya. 2013;53(3):25-30.
16. Nakaz MOZ Ukrayiny vid 27 chervnya 2013 №555. Khronichne obstruktyvne zakhvoryuvannya leheni. Adaptovana klinichna nastanova, zasnovana na dokazakh [Chronic obstructive pulmonary disease. Adapted evidence-based clinical guideline]. [Ukrainian]. Available from: http://mtd.dec.gov.ua/images/dodatki/2013_555_ HOZL/2013_555_hozl_kn.pdf
17. Feshchenko YuI, Gavrysyuk VK, Dzyublyk OYa, Mostovoy YuM, Pertseva TO, Polyanska MO, ta in. Adaptovana klinichna nastanova: khronichne obstruktyvne zakhvoryuvannya lehen [Adapted clinical guideline: chronic obstructive pulmonary disease] Ukr Pulmon Zh. 2020;3:5-36. [Ukrainian]. https://doi.org/10.31215/2306-4927-2020-109- 3-5-36
18. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2020 report. 2020. Available from: https://goldcopd.org/wp-content/uploads/2019/12/GOLD-2020-FINALver1.2- 03Dec19_WMV.pdf
19. Gavrysyuk VK. Chronic cor pulmonale. Praktychna angiologiya. 2008;4(15). Avaiable from: https://angiology.com.ua/ua/archive/2008/4%2815%29/article-155/ hronicheskoe-legochnoe-serdce
20. Nakaz MOZ Ukrayiny №2857 vid 23.12.2021 Pro zatverdzhennya Unifikovanoho klinichnoho protokolu pervynnoyi, vtorynnoyi (spetsializovanoyi) ta tretynnoyi (vysokospetsializovanoyi) medychnoyi dopomohy «Stabilʹna ishemichna khvoroba sertsya». [Ukrainian]. Available from: https://zakon.rada.gov.ua/rada/show/v2857282-21#Text
21. Malchevska TY. Hemostaziolohichni osoblyvosti plazmy u patsiyentiv iz stabilʹnoyu ishemichnoyu khvoroboyu z poyednanoyu patolohiyeyu [The hemostasis changes in patients with stable ischemic heart disease associated with comorbid states]. Visnyk naukovykh doslidzhenʹ. 2015;3:59-62. [Ukrainian]. https://doi.org/10.11603/1681-276Х.2015.3.5193
22. Austin V, Crack PJ, Bozinovski S, Miller AA, Vlahos R. COPD and stroke: are systemic inflammation and oxidative stress the missing links? Clin Sci (Lond). 2016;130:1039–50. PMID: 27215677. PMCID: PMC4876483. https://doi.org/10.1042/CS20160043
23. Zirlik A, Bode Ch, Gawaz M. Platelets, Haemostasis and Inflammation. Springer; 2017. 300 p. https://doi.org/10.1007/978- 3-319-66224-4